经口机器人手术作为头颈癌挽救性治疗是否有用:一项系统综述与荟萃分析
该研究遵循JBI有效性系统综述方法,检索PubMed、Embase和Scopus三个数据库,从679项研究中筛选纳入15项,分析515例患者的资料。中位随访时间至47个月,平均住院日8.5天,2年总生存率为73.8%、无病生存率为56.1%。与原发性头颈癌相比,总生存和无病生存的风险比分别为0.35(95%CI,0.18-0.67)和0.44(95%CI,0.22-0.88)。
要点
- TORS挽救性治疗515例既往放疗野内复发、残留或第二原发头颈癌患者,2年总生存率73.8%、无病生存率56.1%。
- 与原发性头颈癌相比,总生存风险比0.35(95%CI,0.18-0.67)、无病生存风险比0.44(95%CI,0.22-0.88)。
- 阳性手术切缘19.4%,与原发性头颈癌相比风险比1.08(95%CI,0.66-1.75);复发率36%(95%CI,24-48.9)。
核心结论
- TORS是既往放疗野内复发、残留和第二原发头颈癌挽救性治疗的新兴技术,生存结局令人鼓舞,与传统开放手术技术相比发病率和死亡率降低。
- 未来研究需要将吞咽数据的收集作为评估功能结局的关键工具,采用更长的随访时间,并处理包括HPV状态和既往辅助治疗在内的混杂因素。
研究设计与样本
- 遵循JBI有效性系统综述方法,检索PubMed、Embase和Scopus三个数据库,共发现679项研究,经筛选和批判性评价后纳入15项。
- 采用Freeman-Tukey反正弦转换统计方法进行比例荟萃分析,采用Mantel-Haenszel统计方法进行比较分析。
- 分析515例患者的数据,中位随访时间至47个月,平均住院日8.5天。
主要发现
- 2年总生存率为73.8%,2年无病生存率为56.1%。
- 与原发性头颈癌相比,总生存的风险比为0.35(95%CI,0.18-0.67),无病生存的风险比为0.44(95%CI,0.22-0.88)。
- 气管造口拔管和鼻胃管依赖的加权平均值分别为9.7天和12.8天,长期气管造口依赖见于0%-11.5%的患者。
- 阳性手术切缘率为19.4%,与原发性头颈癌相比风险比为1.08(95%CI,0.66-1.75)。
- 复发率为36%(95%CI,24-48.9),合并并发症率为32.3%,其中92%的并发症为Clavien Dindo 2级或3级。
局限性
- 未来研究需要将吞咽数据的收集作为评估功能结局的关键工具。
- 未来研究需要采用更长的随访时间。
- 未来研究需要处理包括HPV状态和既往辅助治疗在内的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Residual, recurrent, and second primary head and neck cancers are on the rise. This is largely driven by a younger age at diagnosis and increasingly targeted chemoradiotherapy options. Salvage surgery remains the only curative intent option in this cohort of patients. With transoral robotic surgery (TORS), achieving good oncological and functional outcomes in primary cancer cohorts, there remains a paucity of synthesized evidence on treating residual, recurrent, or second primary disease in previously irradiated fields. METHODS: Conducted in accordance with the JBI's methodology for systematic reviews of effectiveness, three databases were searched including PubMed, Embase, and Scopus. This study represents the largest systematic review till date finding 679 studies and including 15 after screening and critical appraisal. A meta-analysis of proportions and comparison was conducted using Freeman-Tukey arcsine transformation statistical method and the Mantel-Haenszel statistical method, respectively. RESULTS: Data from 515 patients was analyzed with a median follow-up time up to 47 months and a mean hospital stay of 8.5 days. Two-year overall survival (OS) rate and disease-free survival (DFS) rate were 73.8% and 56.1%, respectively. Compared to primary head and neck cancer, risk ratios for OS and DFS were 0.35 (95% CI, 0.18-0.67) and 0.44 (95% CI, 0.22-0.88). Weighted mean for tracheostomy decannulation and nasogastric dependence was 9.7 and 12.8 days, respectively, with long term tracheostomy dependence in 0%-11.5% of patients. Positive surgical margins were obtained in 19.4% with a risk ratio of 1.08 (95% CI, 0.66-1.75) when compared to primary head and neck cancer. Recurrence rate was 36% (95% CI, 24-48.9). Pooled complication rate was 32.3% with 92% of complications being classed as Clavien Dindo grade 2 or 3. CONCLUSION: TORS is an emerging technique for salvage in recurrent, residual, and second primary head and neck cancers in previously irradiated fields. Survival outcomes are encouraging with decreased morbidity and mortality rates when compared to traditional open surgical techniques. Future studies need to mandate collection of swallowing data as a key tool to evaluate functional outcomes, deploy longer follow-up times, and address confounding factors including HPV status and prior adjuvant therapy.
引用
- Goel S, Gunasekera D, Krishnan G, et al. Is transoral robotic surgery useful as a salvage technique in head and neck cancers: a systematic review and meta analysis. Head Neck. 2024. PMID: 39737644. doi:10.1002/hed.28021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。